Alto Neuroscience plans added Phase 3 trial for depression drug ALTO-207
The company disclosed plans to expand development of ALTO-207 alongside a preliminary cash update as of June 30, 2026.
Alto Neuroscience, Inc. said on July 13, 2026 that it plans to speed up and broaden clinical work on its lead candidate, ALTO-207. The company intends to add another planned Phase 3 study of ALTO-207 used alone to treat treatment-resistant depression.1 The filing did not include a start date, enrollment target, or expected readout timing for the new study.
Alongside the pipeline update, Alto Neuroscience reported a preliminary cash figure. Based on preliminary estimates, the company said its cash, cash equivalents and restricted cash totaled approximately $244.2 million as of June 30, 2026.1
The company flagged that this figure is not final. The amount has not gone through audit, review, or compilation by Alto Neuroscience's independent registered public accounting firm.1 The company said its final cash position for the quarter could differ from this preliminary estimate once it finishes its full accounting close, and any differences could be material.1
The 8-K did not disclose quarterly revenue, expenses, or a stated cash runway estimate beyond the balance figure itself. Alto Neuroscience's forward-looking statement language noted that its comments on clinical development plans for ALTO-207 are subject to risks and uncertainties that could cause actual results to differ from what the company currently expects.1 The filing pointed investors to Alto Neuroscience's Annual Report on Form 10-K for the year ended December 31, 2025 and other SEC filings for a fuller discussion of business risks.1
The report was signed by Amit Etkin, M.D., Ph.D., President and Chief Executive Officer, dated July 13, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.